ABBOTT ARCHITECT CORE ASSAY

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P080023 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for migration of the architect® core¿ assay to a newarchitect® i system family member, the architect® i 1000sr. The architect core reagent kit device is indicated for:the architect core assay is a chemiluminescent microparticle immunoassay(cmia) for the qualitative detection of igg and igm antibodies to hepatitis b coreantigen (anti-hbc) in human adult and pediatric serum and plasma (dipotassium edta, lithium heparin, sodium heparin) and neonatal serum. It is intended as an aid in the diagnosis of acute, chronic, or resolved hepatitis b virus (hbv) infection in conjunction with other laboratory results and clinical information.

DeviceABBOTT ARCHITECT CORE ASSAY
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantAbbott Laboratories
Date Received2009-06-19
Decision Date2009-12-10
PMAP080023
SupplementS001
Product CodeLOM
Advisory CommitteeMicrobiology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Laboratories 100 Abbott Park Rd. ap5n-2, Dept. 09vb abbott Park, IL 60064

Supplemental Filings

Supplement NumberDateSupplement Type
P080023Original Filing
S039 2023-01-06 30-day Notice
S038 2022-09-27 30-day Notice
S037 2022-09-14 30-day Notice
S036 2021-11-18 30-day Notice
S035 2021-11-09 30-day Notice
S034 2021-02-09 Real-time Process
S033 2020-03-16 Normal 180 Day Track No User Fee
S032 2020-03-16 Normal 180 Day Track No User Fee
S031
S030 2018-10-12 30-day Notice
S029 2018-07-13 30-day Notice
S028 2017-12-21 Normal 180 Day Track
S027 2015-07-16 30-day Notice
S026 2014-11-13 30-day Notice
S025 2014-09-19 30-day Notice
S024 2013-10-30 30-day Notice
S023 2013-10-28 30-day Notice
S022 2013-09-04 30-day Notice
S021 2013-02-15 30-day Notice
S020 2013-02-11 30-day Notice
S019 2012-11-19 30-day Notice
S018 2012-11-15 30-day Notice
S017 2012-11-13 30-day Notice
S016 2012-11-01 30-day Notice
S015 2012-08-03 30-day Notice
S014 2012-03-22 30-day Notice
S013 2012-03-15 30-day Notice
S012 2011-11-23 Special (immediate Track)
S011 2011-10-28 135 Review Track For 30-day Notice
S010 2011-10-28 30-day Notice
S009 2011-05-25 30-day Notice
S008 2011-05-04 Normal 180 Day Track No User Fee
S007 2011-04-18 30-day Notice
S006 2011-02-17 Normal 180 Day Track No User Fee
S005 2010-12-28 135 Review Track For 30-day Notice
S004 2010-12-22 Special (immediate Track)
S003 2010-11-01 Normal 180 Day Track No User Fee
S002 2010-06-22 Normal 180 Day Track No User Fee
S001 2009-06-19 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
00380740011123 P080023 001
00380740011116 P080023 001
00380740011109 P080023 001
00380740136666 P080023 028
00380740136659 P080023 028
00380740136642 P080023 028
00380740136635 P080023 028

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.